New medical therapies for heart failure

Nature Reviews Cardiology

Volumn 12, Issue 12, 2015, Pages 730-740

  Von Lueder, Thomas G ^a   Krum, Henry ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; CENDERITIDE; DIURETIC AGENT; GUANYLATE CYCLASE ACTIVATOR; INOTROPIC AGENT; NEU DIFFERENTIATION FACTOR; OMECAMTIV MECARBIL; SACUBITRIL PLUS VALSARTAN; SERELAXIN; URODILATIN; VASODILATOR AGENT; AMIDE; AMINOBUTYRIC ACID DERIVATIVE; ATRIAL NATRIURETIC FACTOR; DIGOXIN; FUMARIC ACID DERIVATIVE; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; SNAKE VENOM; TETRAZOLE DERIVATIVE;

CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; DIURESIS; FOLLOW UP; GLOMERULUS FILTRATION; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; MORBIDITY; NATRIURESIS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMIC VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE CELL;

AMIDES; AMINOBUTYRATES; ATRIAL NATRIURETIC FACTOR; DIGOXIN; FUMARATES; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PEPTIDE FRAGMENTS; SNAKE VENOMS; TETRAZOLES;

EID: 84947863897     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.137     Document Type: Review

References (165)

1. Go, A. S. et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129, e28-e292 (2014).
2. Adams, K. F. Jr et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209-216 (2005).
3. Munger, M. A. & Carter, O. Epidemiology and practice patterns of acute decompensated heart failure. Am. J. Health Syst. Pharm. 60 (Suppl. 4), S3-S6 (2003).
4. Follath, F. et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 37, 619-626 (2011).
5. Ezekowitz, J. A., Bakal, J. A., Kaul, P., Westerhout, C. M. & Armstrong, P. W. Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. Eur. J. Heart Fail. 10, 308-314 (2008).
6. Skali, H. et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur. J. Heart Fail. 16, 560-565 (2014).
7. Senni, M. et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int. J. Cardiol. 173, 163-169 (2014).
8. Greene, S. J. et al. The vulnerable phase after hospitalization for heart failure. Nat. Rev. Cardiol. 12, 220-229 (2015).
9. Eastwood, C. A. et al. Determinants of early readmission after hospitalization for heart failure. Can. J. Cardiol. 30, 612-618 (2014).
10. Cheng, R. K. et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am. Heart J. 168, 721-730 (2014).
11. McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012).
12. Verbrugge, F. H. et al. Uptitration of renin-angiotensin system blocker and-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions. Am. J. Cardiol. 112, 1913-1920 (2013).
13. Schulz-Knappe, P. et al. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin. Wochenschr. 66, 752-759 (1988).
14. de Bold, A. J., Borenstein, H. B., Veress, A. T. & Sonnenberg, H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28, 89-94 (1981).
15. Rosenzweig, A. & Seidman, C. E. Atrial natriuretic factor and related peptide hormones. Annu. Rev. Biochem. 60, 229-255 (1991).
16. Burnett, J. C. Jr, Granger, J. P. & Opgenorth, T. J. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am. J. Physiol. 247, F863-F866 (1984).
17. Chinkers, M. et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 338, 78-83 (1989).
18. Forssmann, W. G., Richter, R. & Meyer, M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem. Cell Biol. 110, 335-357 (1998).
19. Saxenhofer, H. et al. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am. J. Physiol. 259, F832-F838 (1990).
20. Kuhn, M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. 93, 700-709 (2003).
21. Potter, L. R., Abbey-Hosch, S. & Dickey, D. M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27, 47-72 (2006).
22. Fuller, F. et al. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J. Biol. Chem. 263, 9395-9401 (1988).
23. Abassi, Z. A. et al. Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition. Am. J. Physiol. 263, E870-E876 (1992).
24. Drummer, C., Fiedler, F., König, A. & Gerzer, R. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J. Am. Soc. Nephrol. 1, 1109-1113 (1991).
25. Goetz, K. et al. Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J. Am. Soc. Nephrol. 1, 867-874 (1990).
26. Kentsch, M., Ludwig, D., Drummer, C., Gerzer, R. & Müller-Esch, G. Haemodynamic and renal effects of urodilatin in healthy volunteers. Eur. J. Clin. Invest. 22, 319-325 (1992).
27. Kentsch, M., Ludwig, D., Drummer, C., Gerzer, R. & Müller-Esch, G. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur. J. Clin. Invest. 22, 662-669 (1992).
28. Mitrovic, V. et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am. Heart J. 150, 1239 (2005).
29. Mitrovic, V. et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur. Heart J. 27, 2823-2832 (2006).
30. Hernandez, A. F. et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am. Heart J. 157, 271-277 (2009).
31. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01661634 (2015).
32. O'Connor, C. M. et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32-43 (2011).
33. Sackner-Bernstein, J. D., Skopicki, H. A. & Aaronson, K. D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111, 1487-1491 (2005).
34. Kristeller, J. L., Papps, H. & Stahl, R. F. Risk of worsening renal function with nesiritide following cardiac surgery. Am. J. Health Syst. Pharm. 63, 2351-2353 (2006).
35. Schweitz, H., Vigne, P., Moinier, D., Frelin, C. & Lazdunski, M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 267, 13928-13932 (1992).
36. Lisy, O., Huntley, B. K., McCormick, D. J., Kurlansky, P. A. & Burnett, J. C. Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 52, 60-68 (2008).
37. Mangiafico, S., Costello-Boerrigter, L. C., Andersen, I. A., Cataliotti, A. & Burnett, J. C. Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J. 34, 886-893 (2013).
38. von Lueder, T. G. et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ. Heart Fail. 6, 594-605 (2013).
39. Dickey, D. M. et al. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 148, 3518-3522 (2007).
40. Dickey, D. M., Burnett, J. C. Jr & Potter, L. R. Novel bifunctional natriuretic peptides as potential therapeutics. J. Biol. Chem. 283, 35003-35009 (2008).
41. Horio, T. et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 144, 2279-2284 (2003).
42. Soeki, T. et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 45, 608-616 (2005).
43. Martin, F. L. et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One 7, e52422 (2012).
44. Lee, C. Y. et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharmacol. 49, 668-673 (2009).
45. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00839007 (2010).
46. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00620308 (2012).
47. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02071602 (2015).
48. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01750905 (2015).
49. Capricor Therapeutics™. Clinical Trials, Cenderitide, Phase II [online], http://capricor.com/clinical-trials/cenderitide/(2015).
50. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/nct02359227 (2015).
51. von Lueder, T. G., Atar, D. & Krum, H. Diuretic use in heart failure and outcomes. Clin. Pharmacol. Ther. 94, 490-498 (2013).
52. Salvador, D. R., Rey, N. R., Ramos, G. C. & Punzalan, F. E. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003178 http://dx.doi.org/10.1002/14651858.CD003178.pub3.
53. Von Lueder, T. G., Atar, D. & Krum, H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol. Ther. 144, 41-49 (2014).
54. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325, 293-302 (1991).
55. McMurray, J. J. et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur. J. Heart Fail. 15, 1062-1073 (2013).
56. McMurray, J. J. et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur. J. Heart Fail. 16, 817-825 (2014).
57. McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993-1004 (2014).
58. Packer, M. et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131, 54-61 (2015).
59. von Lueder, T. G. et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ. Heart Fail. 8, 71-78 (2015).
60. Jhund, P. S. et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ. Heart Fail. 7, 953-959 (2014).
61. Bodey, F., Hopper, I. & Krum, H. Neprilysin inhibitors preserve renal function in heart failure. Int. J. Cardiol. 179, 329-330 (2015).
62. Wang, B. H. et al. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. Int. J. Cardiol. 186, 104-105 (2015).
63. Voors, A. A. et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur. J. Heart Fail. 17, 510-517 (2015).
64. Messerli, F. H. & Nussberger, J. Vasopeptidase inhibition and angio-oedema. Lancet 356, 608-609 (2000).
65. Hegde, L. G. et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J. Cardiovasc. Pharmacol. 57, 495-504 (2011).
66. von Lueder, T. G. & Krum, H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc. Drugs Ther. 27, 171-179 (2013).
67. McMurray, J. et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur. Heart J. 36, 434-439 (2015).
68. Solomon, S. D. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380, 1387-1395 (2012).
69. Rossi, A. et al. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ. Heart Fail. 7, 1042-1049 (2014).
70. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01920711 (2014).
71. Supaporn, T. et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3', 5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 50, 1718-1725 (1996).
72. Schmidt, P., Schramm, M., Schröder, H. & Stasch, J. P. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur. J. Pharmacol. 468, 167-174 (2003).
73. Evgenov, O. V. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5, 755-768 (2006).
74. Stasch, J. P. et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 410, 212-215 (2001).
75. Boerrigter, G. et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 49, 1128-1133 (2007).
76. Irvine, J. C. et al. The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy. PLoS One 7, e44481 (2012).
77. Fraccarollo, D. et al. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res. Cardiol. 109, 421 (2014).
78. Stasch, J. P., Dembowsky, K., Perzborn, E., Stahl, E. & Schramm, M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. 135, 344-355 (2002).
79. Zanfolin, M. et al. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J. Cardiovasc. Pharmacol. 47, 391-395 (2006).
80. Krieg, T. et al. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur. Heart J. 30, 1607-1613 (2009).
81. Mueck, W. & Frey, R. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. Clin. Pharmacokinet. 49, 119-129 (2010).
82. Gheorghiade, M. et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail. Rev. 18, 123-134 (2013).
83. Ghofrani, H. A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369, 319-329 (2013).
84. Erdmann, E. et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur. Heart J. 34, 57-67 (2013).
85. Lapp, H. et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119, 2781-2788 (2009).
86. Gheorghiade, M. et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur. J. Heart Fail. 14, 1056-1066 (2012).
87. Bonderman, D. et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128, 502-511 (2013).
88. Pieske, B. et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur. J. Heart Fail. 16, 1026-1038 (2014).
89. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01951625 (2015).
90. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01951638 (2015).
91. Du, X. J., Bathgate, R. A., Samuel, C. S., Dart, A. M. & Summers, R. J. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat. Rev. Cardiol. 7, 48-58 (2010).
92. Teerlink, J. R. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429-1439 (2009).
93. Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29-39 (2013).
94. Filippatos, G. et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur. Heart J. 35, 1041-1050 (2014).
95. Metra, M. et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J. Am. Coll. Cardiol. 61, 196-206 (2013).
96. Ponikowski, P. et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur. Heart J. 35, 431-441 (2014).
97. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01870778 (2015).
98. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02064868 (2015).
99. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02007720 (2015).
100. McMurray, J. J. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur. J. Heart Fail. 13, 929-936 (2011).
101. Emdin, C. A., Callender, T., Cao, J., McMurray, J. J. & Rahimi, K. Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. Am. J. Cardiol. 116, 155-161 (2015).
102. Clark, H., Krum, H. & Hopper, I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur. J. Heart Fail. 16, 41-48 (2014).
103. Lang, C. C. & Struthers, A. D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat. Rev. Cardiol. 10, 125-134 (2013).
104. Krum, H. Role of renin in heart failure and therapeutic potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst. 9, 177-180 (2008).
105. Krum, H. & Maggioni, A. Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. Clin. Cardiol. 33, 536-541 (2010).
106. Birkenhäger, W. H. & Staessen, J. A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 370, 195-196 (2007).
107. Nussberger, J., Wuerzner, G., Jensen, C. & Brunner, H. R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1-E8 (2002).
108. McMurray, J. J. et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
109. Sidik, N. P. et al. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. Cardiovasc. Drugs Ther. 25, 315-321 (2011).
110. Pitt, B. et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur. J. Heart Fail. 13, 755-764 (2011).
111. Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
112. Gheorghiade, M. et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur. J. Heart Fail. 13, 100-106 (2011).
113. Gheorghiade, M. et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309, 1125-1135 (2013).
114. Maggioni, A. P. et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur. Heart J. 34, 3117-3127 (2013).
115. Krum, H. et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur. J. Heart Fail. 13, 107-114 (2011).
116. McMurray, J. J. et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur. J. Heart Fail. 14, 341-343 (2012).
117. Krum, H. et al. Losing ALTITUDE How should ASTRONAUT launch into ATMOSPHERE. Eur. J. Heart Fail. 15, 1205-1207 (2013).
118. Milano, C. A. et al. Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. N. C. Med. J. 67, 110-115 (2006).
119. Toma, M. & Starling, R. C. Inotropic therapy for end-stage heart failure patients. Curr. Treat. Options Cardiovasc. Med. 12, 409-419 (2010).
120. Monrad, E. S., Baim, D. S., Smith, H. S. & Lanoue, A. S. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73, 168-174 (1986).
121. Francis, G. S., Bartos, J. A. & Adatya, S. Inotropes. J. Am. Coll. Cardiol. 63, 2069-2078 (2014).
122. Packer, M. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325, 1468-1475 (1991).
123. Shizukuda, Y. et al.-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am. J. Physiol. 275, H961-H968 (1998).
124. De Backer, D. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med. 362, 779-789 (2010).
125. DiBianco, R. et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N. Engl. J. Med. 320, 677-683 (1989).
126. Metra, M. et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur. Heart J. 30, 3015-3026 (2009).
127. Orstavik, O. et al. Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br. J. Pharmacol. 171, 5169-5181 (2014).
128. Follath, F. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360, 196-202 (2002).
129. Unverzagt, S. et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD009669 http://dx.doi.org/10.1002/14651858.CD009669.pub2.
130. Morgan, B. P. et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med. Chem. Lett. 1, 472-477 (2010).
131. Malik, F. I. et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331, 1439-1443 (2011).
132. Shen, Y. T. et al. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ. Heart Fail. 3, 522-527 (2010).
133. Teerlink, J. R. et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378, 667-675 (2011).
134. Cleland, J. G. et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378, 676-683 (2011).
135. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01300013 (2014).
136. Valentova, M. & von Haehling, S. An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. Expert Opin. Investig. Drugs 23, 573-578 (2014).
137. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01786512 (2015).
138. Greenberg, B. H. et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 3, 22-29 (2015).
139. Lee, K. F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398 (1995).
140. Camenisch, T. D., Schroeder, J. A., Bradley, J., Klewer, S. E. & McDonald, J. A. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat. Med. 8, 850-855 (2002).
141. Britsch, S. The neuregulin-I/ErbB signaling system in development and disease. Adv. Anat. Embryol. Cell Biol. 190, 1-65 (2007).
142. Gassmann, M. et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394 (1995).
143. Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459-465 (2002).
144. Garciá-Rivello, H. et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am. J. Physiol. Heart Circ. Physiol. 289, H1153-H1160 (2005).
145. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
146. Liu, X. et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 48, 1438-1447 (2006).
147. Gao, R. et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 55, 1907-1914 (2010).
148. Hill, M. F. et al. Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1 improves left ventricular function, gene and protein expression in rats after myocardial infarction. PLoS One 8, e55741 (2013).
149. Galindo, C. L. et al. Anti-remodeling and anti-fibrotic effects of the neuregulin-1 glial growth factor 2 in a large animal model of heart failure. J. Am. Heart Assoc. 3, e000773 (2014).
150. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/results/NCT01258387 (2014).
151. McCurley, A. & Jaffe, I. Z. Mineralocorticoid receptors in vascular function and disease. Mol. Cell. Endocrinol. 350, 256-265 (2012).
152. Funder, J. W. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog. Cardiovasc. Dis. 52, 393-400 (2010).
153. Young, M. J. & Funder, J. W. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J. Hypertens. 20, 1465-1468 (2002).
154. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).
155. Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
156. Krum, H. & Liew, D. Eplerenone in the treatment of chronic heart failure. Expert. Rev. Cardiovasc. Ther. 2, 315-320 (2004).
157. Edwards, C. R. et al. Localisation of 11-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2, 986-989 (1988).
158. Sica, D. A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev. 10, 23-29 (2005).
159. Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543-551 (2004).
160. Albert, N. M. et al. Use of aldosterone antagonists in heart failure. JAMA 302, 1658-1665 (2009).
161. Rossignol, P. et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ. Heart Fail. 7, 51-58 (2014).
162. Bärfacker, L. et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7, 1385-1403 (2012).
163. Kolkhof, P. et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64, 69-78 (2014).
164. Pitt, B. et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453-2463 (2013).
165. Pitt, B. et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur. J. Heart Fail. 17, 224-232 (2015).